

10/575263

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: KATAOKA=3

In re Application of:)	Conf. No.: Not Yet Known
)	
Motoyuki KATAOKA et al.)	Art Unit: Not Yet Known
)	
I.A. No.: PCT/JP2004/015127)	Examiner: Not Yet Known
I.A. Filed: October 14, 2004)	
)	
U.S. Appln: Not Yet Assigned)	Washington D.C.
Filing Date: April 10, 2006)	
)	
For: THERAPEUTIC AGENTS FOR)	September 25, 2006
RENAL DISEASE)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
 U.S. Patent and Trademark Office
 Customer Service Window
 Randolph Building, Mail Stop Amendment
 401 Dulany Street
 Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office,

either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

3. Documents AB and AC are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states an English translation of each document AB and AC (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Sheridan Neimark
Registration No. 20,520

SN:ma
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\Y\YUAS\Kataoka3\Pto\2006-09-25 IDS Form.doc

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				International Appln. No.	PCT/JP2004/015127
(use as many sheets as necessary)				I.A. Filing Date	October 14, 2004
				First Named Inventor	Motoyuki KATAOKA
				Group Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	1	of	1	Attorney Docket Number	KATAOKA=3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	AA	Florian TOGEL et al., "Hematopoietic Stem Cell Mobilization-Associated Granulocytosis Severely Worsens Acute Renal Failure", <u>J. Am. Soc. Nephrol</u> , Vol. 15, pp. 1261-1267, 2004.			
	AB	Kanji Shishido et al., "The effects and pharmacokinetics of rhG-CSF on the treatment of neutropenia in patients with renal failure", <u>Jpn. J. Nephrol</u> , Vol. 33, No. 10, pp. 973-981, August 31, 1991			
	AC	Akiko SAEKI et al., "Impaired neutrophil function in chronic renal failure-Disregulation of surface adhesion molecule expression and phagocytosis", <u>Jpn. J. Nephrol. Society</u> , Vol. 38, No. 12, pp. 585-594, September 17, 1996.			
	AD	F. Strutz et al., "On the Progression of Chronic Renal Disease", <u>Nephron</u> , vol. 69, pp. 371-379, 1995.			

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation attached.